Diversity of envelope genes from an uncloned stock of SIVmac251.

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathog (2016) 1.42

Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol (2013) 1.18

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol (2013) 1.16

The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1. Cell Host Microbe (2012) 1.06

Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother (2014) 0.99

Significant genetic heterogeneity of the SIVmac251 viral swarm derived from different sources. AIDS Res Hum Retroviruses (2011) 0.89

In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection. PLoS Pathog (2014) 0.85

Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus. J Virol (2012) 0.81

Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques. Virology (2014) 0.81

Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. J Virol (2014) 0.80

Identification and characterization of a long non-coding RNA up-regulated during HIV-1 infection. Virology (2017) 0.75

Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94

Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27

Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science (1990) 8.07

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17

HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16

The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1990) 5.79

Extensive variation of human immunodeficiency virus type-1 in vivo. Nature (1988) 5.02

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol (2005) 4.61

HIV vaccine research: the way forward. Science (2008) 3.86

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol (1996) 3.84

Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol (1991) 3.46

Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol (1992) 3.16

Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol (1997) 2.90

Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol (1993) 2.70

Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69

Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses (1994) 2.63

A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol (2008) 2.27

The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol (2000) 2.03

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01

Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. Int J Cancer (1988) 1.96

Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J Virol (2001) 1.95

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol (2003) 1.80

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol (2008) 1.72

Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J Virol (2000) 1.57

Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology (2001) 1.52

Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry. Virology (1993) 1.45

Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements. J Virol (1996) 1.39

Origins of simian immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol (1995) 1.32

DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A (2009) 1.30

Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol (2003) 1.24

Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol (2005) 1.13

Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies. PLoS Pathog (2009) 0.96

HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48

Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33

Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31

Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45

Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog (2009) 4.24

Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog (2009) 4.18

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25

TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol (2010) 3.21

HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol (2002) 2.63

Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med (2002) 2.51

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33

Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci U S A (2006) 2.16

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01

A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol (2003) 1.80

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76

Analysis of copy number variation in the rhesus macaque genome identifies candidate loci for evolutionary and human disease studies. Hum Mol Genet (2008) 1.73

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology (2006) 1.67

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67

CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol (2002) 1.66

ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60

Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol (2003) 1.60

Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med (2006) 1.55

Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44

Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol (2002) 1.44

Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. Am J Pathol (2004) 1.43

Cloning and analysis of microRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus. Virology (2007) 1.40

MHC heterozygote advantage in simian immunodeficiency virus-infected Mauritian cynomolgus macaques. Sci Transl Med (2010) 1.38

Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol (2004) 1.31

Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol (2003) 1.28

Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol (2008) 1.27

The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J Virol (2011) 1.26

Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol (2003) 1.24

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine (2011) 1.23

Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol (2003) 1.19

Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J Virol (2005) 1.17

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol (2013) 1.16

Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol (2005) 1.13

A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol (2002) 1.12

A genetic system for rhesus monkey rhadinovirus: use of recombinant virus to quantitate antibody-mediated neutralization. J Virol (2006) 1.12

Retroviral recombination in vivo: viral replication patterns and genetic structure of simian immunodeficiency virus (SIV) populations in rhesus macaques after simultaneous or sequential intravaginal inoculation with SIVmac239Deltavpx/Deltavpr and SIVmac239Deltanef. J Virol (2005) 1.10

Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol (2008) 1.09

The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol (2012) 1.09

Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07

The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1. Cell Host Microbe (2012) 1.06

Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor. J Virol (2002) 1.05

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol (2011) 1.05

A novel approach for producing lentiviruses that are limited to a single cycle of infection. J Virol (2004) 1.03

Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology (2006) 1.02

Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01

Refinement of primate copy number variation hotspots identifies candidate genomic regions evolving under positive selection. Genome Biol (2011) 0.99

Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J Virol (2005) 0.99

A brief history of TRIM5alpha. AIDS Rev (2007) 0.98

APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host. PLoS Pathog (2013) 0.98

Host genes important to HIV replication and evolution. Cold Spring Harb Perspect Med (2012) 0.95

Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J Virol (2008) 0.94

Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions. J Virol (2011) 0.94

Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus. J Virol (2011) 0.91

Gain-of-sensitivity mutations in a Trim5-resistant primary isolate of pathogenic SIV identify two independent conserved determinants of Trim5α specificity. PLoS Pathog (2013) 0.91

Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate. J Virol (2010) 0.90

Pushing the endogenous envelope. Philos Trans R Soc Lond B Biol Sci (2013) 0.88

Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J Virol (2011) 0.87

Functional contributions of carbohydrate on AIDS virus glycoprotein. Yale J Biol Med (2010) 0.87

Glycoprotein gene sequence variation in rhesus monkey rhadinovirus. Virology (2010) 0.86

An AIDS vaccine: no time to give up. Lancet (2004) 0.86

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology (2014) 0.85

Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology (2007) 0.85

Extreme dependence of gH and gL expression on ORF57 and association with highly unusual codon usage in rhesus monkey rhadinovirus. J Virol (2008) 0.83

p6gag of human and simian immunodeficiency viruses is tolerant to small in-frame deletions downstream of the late domain. Virology (2005) 0.83

Infection and persistence of rhesus monkey rhadinovirus in immortalized B-cell lines. J Virol (2006) 0.81

Susceptibility to repeated, low-dose, rectal SHIVSF162P3 challenge is independent of TRIM5 genotype in rhesus macaques. AIDS Res Hum Retroviruses (2013) 0.81

Rhesus monkey rhadinovirus uses eph family receptors for entry into B cells and endothelial cells but not fibroblasts. PLoS Pathog (2013) 0.81

Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus. J Virol (2012) 0.81

Rhesus monkey rhadinovirus ORF57 induces gH and gL glycoprotein expression through posttranscriptional accumulation of target mRNAs. J Virol (2011) 0.81

Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops. J Virol (2007) 0.81

A novel recombinant retrovirus in the genomes of modern birds combines features of avian and mammalian retroviruses. J Virol (2013) 0.80

Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages. J Virol (2010) 0.79

Flow cytometry based identification of simian immunodeficiency virus Env-specific B lymphocytes. J Immunol Methods (2011) 0.78

Assisted suicide for retroviruses. Nat Biotechnol (2007) 0.78

Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques. PLoS One (2013) 0.77

The evolution of infectious agents in relation to sex in animals and humans: brief discussions of some individual organisms. Ann N Y Acad Sci (2011) 0.76

PRA1 co-localizes with envelope but does not influence primate lentivirus production, infectivity or envelope incorporation. J Gen Virol (2005) 0.76

Elevated rate of fixation of endogenous retroviral elements in Haplorhini TRIM5 and TRIM22 genomic sequences: impact on transcriptional regulation. PLoS One (2013) 0.75

Localization of productively infected cells in the spleen and Peyer's patches of rhesus macaques during acute infection with SIVmac239Δnef-enhanced green fluorescent protein. AIDS Res Hum Retroviruses (2014) 0.75

Acquisition and processing of nonhuman primate samples for genetic and phylogenetic analyses. Methods (2009) 0.75

A plea for justice for jailed medical workers. Science (2006) 0.75